Navigation Links
Cellceutix Cancer Drug Kevetrin™ Shows No Genotoxicity in Study
Date:3/2/2011

its annual report on Form 10-K.

Kevetrin, KM133, and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.


'/>"/>
SOURCE Cellceutix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 Ardelyx, Inc. (NASDAQ: ... gastrointestinal and cardio-renal diseases, today announced that Sanofi ... and license agreement for Ardelyx,s portfolio of NaP2b ... payment associated with termination and the return of ... Sanofi entered into an option and license agreement ...
(Date:9/1/2015)... Sept. 1, 2015  Dynatronics Corporation (NASDAQ: ... at the First Annual Ladenburg Thalmann Healthcare Conference ... Kelvyn H. Cullimore, Jr. , Chairman and ... investment representatives on Tuesday, September 29 at 10:30 ... Conference will showcase leading-edge companies in the healthcare ...
(Date:9/1/2015)... -- Dr. Cindy Orser , the Chief Science Officer ... of DigiPath, Inc. (OTCQB: DIGP), was recently interviewed ... consistency in today,s medical cannabis testing industry. In her ... she explained that the state-to-state variations in cannabis laws ... makes standardization impossible. Dr. Orser is ...
Breaking Medicine Technology:Ardelyx Regains NaP2b Program from Sanofi 2Ardelyx Regains NaP2b Program from Sanofi 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3
... China , April 29 /PRNewswire-Asia-FirstCall/ -- China Pharma,Holdings, Inc. (NYSE ... pharmaceuticals company in China , today announced,that it has retained CCG ... , , ... to working with CCG to establish more effective and,transparent communications channels with ...
... , April 29 Royal Philips Electronics ( ... provider of integration solutions in healthcare, to deploy the Orion Health Rhapsody® ... , , ... , , ...
Cached Medicine Technology:China Pharma Holdings, Inc. Retains CCG Investor Relations 2China Pharma Holdings, Inc. Retains CCG Investor Relations 3China Pharma Holdings, Inc. Retains CCG Investor Relations 4China Pharma Holdings, Inc. Retains CCG Investor Relations 5Philips and Orion Health Partner to Deliver on Enterprise Interoperability 2Philips and Orion Health Partner to Deliver on Enterprise Interoperability 3Philips and Orion Health Partner to Deliver on Enterprise Interoperability 4
(Date:9/1/2015)... ... 02, 2015 , ... The Journal of Pain Research has published ... ”. , As corresponding author Mr Christopher Malone says “Migraine headache is a painful ... endeavoured to better understand how migraine headaches impact the lives of migraineurs. We asked ...
(Date:9/1/2015)... ... 01, 2015 , ... Stress comes in many different forms ... changes can lead to very serious, life-altering events. Fortunately nature offers a range ... supplement manufacturer MediHerb has coupled therapeutic doses of Rhodiola and Schisandra ...
(Date:9/1/2015)... ... September 01, 2015 , ... Georgia State ... universities across the country in stemming sexual assaults on their campuses. , The ... a consortium of sexual assault researchers and student affairs professionals responding to calls ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... vacuum that creates negative pressure inside a wound to remove exudates, fluid, and ... treatment devices (comprising portable devices, stand-alone devices, disposable devices, and canisters, etc.) is ...
(Date:9/1/2015)... PA (PRWEB) , ... September 01, 2015 , ... The ... 18 at The ACE Club and Green Valley Country Club in Lafayette Hill, PA. ... has raised more than $13.5 million for programs and services designed to support patients ...
Breaking Medicine News(10 mins):Health News:Migraine, treatment, comorbidities, and quality of life published by Dove Medical Press 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3
... It prevents many complications of chronic disease, experts ... who strictly control their blood sugar levels also ... disease, British researchers report. , There have been ... reducing blood sugar levels in diabetic patients in ...
... (Pink Sheets: FTER), owner and operator of the "A ... today that the documentary "Intervention," which features this Forterus ... Network at 7 p.m. Eastern and Pacific on Monday, ... people who are seeking a route to redemption from ...
... Gerberding, former Director of the Center for Disease Control and Prevention ... and of CAI International Inc., have been elected to the ... ... Washington, D.C. (Vocus) May 22, 2009 -- Dr. Julie Gerberding, ...
... African American women with late stage breast cancer refused chemotherapy ... July 1, 2009 issue of CANCER , a peer-reviewed ... more efforts are needed to ensure that all women with ... African American women have almost twice the rate of advanced ...
... can be linked to different invasive breast cancer subtypes. ... open access journal Breast Cancer Research , suggests ... are associated with different kinds of tumor. , Marilyn ... a team of researchers who used data from the ...
... Delivery of PMTCTGENEVA, May 21 In a dramatic ... of the International Treatment Preparedness Coalition (ITPC) and AIDS-Free ... members of UNAIDS and WHO to present ITPC,s latest ... Failing Children: HIV, Vertical Transmission and Women,s Health, ...
Cached Medicine News:Health News:Strict Blood Sugar Control Lowers Heart Risks in Diabetics 2Health News:Strict Blood Sugar Control Lowers Heart Risks in Diabetics 3Health News:Julie Gerberding and Hiromitsu Ogawa Join Accordia Board 2Health News:African-American women with advanced breast cancer often forego vital treatment 2Health News:AIDS Treatment Activists Push UNAIDS and WHO to Meet Commitments to Reduce HIV in Women and Newborns 2Health News:AIDS Treatment Activists Push UNAIDS and WHO to Meet Commitments to Reduce HIV in Women and Newborns 3
The Rheumatoid Factor (RF) assay is used for the quantitative analysis of rheumatoid factor in human serum....
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w...
... The Carriazo-Pendular microkeratome is based ... of the cornea during the cut., ... applanated evenly from the beginning of ... ensures that the intraocular pressure does ...
Medicine Products: